市場調査レポート - 74735

ドラッグデリバリー技術:市場力学・今後の市場機会・ライフサイクル戦略

Drug Delivery Technologies - Current Market Dynamics, Future Market Opportunities and Lifecycle Strategies

発行 Arrowhead Publishers
出版日 ページ情報 英文 283 Pages
価格
ドラッグデリバリー技術:市場力学・今後の市場機会・ライフサイクル戦略 Drug Delivery Technologies - Current Market Dynamics, Future Market Opportunities and Lifecycle Strategies
出版日: 2008年09月24日 ページ情報: 英文 283 Pages
概要

当報告書では、既存・新規ドラッグデリバリー技術の概要、医薬品・バイオテクノロジー産業における各種アプリケーションの動向などについて調査分析し、世界のドラッグデリバリー産業における市場機会・脅威、主要企業のプロファイル、主要技術市場の分析と見通し、売上動向などをまとめ、概略下記の構成でお届けいたします。

第1章 イントロダクション

  • 各種ドラッグデリバリーシステムの価値
  • ドラッグデリバリー・製品の差異化
  • ドラッグデリバリーと特許の延長
  • 組成変更の最適なタイミング
  • ドラッグデリバリーによるR&Dリターンの最大化
  • ドラッグデリバリー部門の市場機会・脅威
  • ドラッグデリバリー企業のビジネスモデル

第2章 ドラッグデリバリー技術の概要

  • 経口ドラッグデリバリー
  • 吸入型ドラッグデリバリー
  • 注射によるドラッグデリバリー
  • 経粘膜ドラッグデリバリー
  • 経皮ドラッグデリバリー
  • ニッチドラッグデリバリー技術

第3章 世界のドラッグデリバリー市場:概要

  • ドラッグデリバリーの重要性

第4章 ドラッグデリバリー市場分析

  • 主要市場区分

第5章 新しいドラッグデリバリー技術:経口ドラッグデリバリー

  • 主要製品プロファイル
  • 主要企業

第6章 新しいドラッグデリバリー技術:吸入型ドラッグデリバリー

  • 主要製品プロファイル
  • 主要企業

第7章 新しいドラッグデリバリー技術:注射によるドラッグデリバリー

  • 主要製品プロファイル
  • 主要企業

第8章 新しいドラッグデリバリー技術:経粘膜ドラッグデリバリー

  • 主要製品プロファイル
  • 主要企業

第9章 新しいドラッグデリバリー技術:経皮ドラッグデリバリー

  • 主要製品プロファイル
  • 主要企業

第10章 新しいドラッグデリバリー技術:ニッチドラッグデリバリー技術

  • 主要製品プロファイル
  • 主要企業

第11章 主要ドラッグデリバリー企業のプロファイル

図表

目次

Abstract

The drug delivery industry has in recent years become a key partner for pharmaceutical companies in their efforts to maximize the patent lives of successful products. Drug delivery companies not only stand to benefit from patent expiry by providing their reformulation services to pharmaceutical companies, but also by producing their own versions of branded products with improved delivery mechanisms. Thus, post-patent expiry sales can be switched from the ethical manufacturer to the drug delivery sector.

Drug Delivery Technologies: Current Market Dynamics, Future Market Opportunities and Lifecycle Strategies is an up-to-date guide that assesses the current state of the drug delivery industry and its application to both the pharmaceutical and biotech industries. While the sector is still dominated by oral technologies, drug delivery systems have expanded to include more novel devices such as needleless injectables, PEGylation platforms and microelectromechanical devices. These technological advances extend the duration of a drug' s action, increase delivery to target sites, reduce delivery to unwanted sites, and maximize drug absorption.

The expanding market for biotechnology and gene-based products, which by their very nature are difficult to administer, represents an emerging opportunity for drug delivery technologies. These technologies are first expected to come to market as reformulations of existing macromolecular therapies, such as insulin. This report analyzes the markets for oral, inhalable, injectable, transmucosal, transdermal and niche drug delivery technologies as they apply to both biotech and traditional pharmacological compounds.

Key Features of This Report

  • A thorough overview of both marketed and emerging drug delivery technologies set to impact the global pharmaceutical market
  • Analysis of the opportunities and threats to the global drug delivery industry
  • Profiles of drug delivery companies along with key financial figures and technology/product portfolios
  • Market analysis and outlook for the leading drug delivery technologies, including oral, injectable, inhalable, transdermal, transmucosal and niche technologies
  • Profiles of key emerging drug delivery technologies and profiles of leading companies, by type of technology
  • An overview of the global drug delivery market, with sales for key drug delivery categories and key products within each one of the them
  • Identification of key areas associated with the successful development of new drug delivery systems
  • Critical assessment of market trends, forecasts and problems in the global drug delivery market
  • Explanations of key technologies and mechanism of action of new drug delivery technologies and products utilizing them
  • Thorough descriptions of important areas of research and development in the drug delivery market

What questions does this report answer?

  • What are the key trends in the field of drug delivery as a whole?
  • What are the major issues involved in the research and development of more effective drug delivery systems?
  • What types of drug delivery technologies are currently in research and development in each of the main drug delivery categories?
  • What is the value of new drug delivery technologies in terms of a product' s lifecycle management?
  • Which new drug delivery systems are likely to provide the best commercial opportunities for their manufacturers?

Highlights of this report

  • Discussion and analysis of the problems associated with the use of traditional drug delivery technologies: lack of patient compliance, considerable adverse effects, inferior clinical efficacy due to the lack of targeted delivery
  • Identification of the hallenges to the development of better, more efficacious drug delivery technologies, with fewer side effects
  • Focused analysis of the global market for major drug delivery technologies: oral, inhalable, injectable, transdermal, transmucosal and topical, as well as niche technologies, such as gene delivery
  • Identification of the major products in research and development utilizing new technologies
  • Highlights of the drug delivery systems that are most likely to impact the global market

Reasons to purchase

  • Provides a comprehensive description of the current state of affairs in the global drug delivery field
  • Provides a comprehensive description of the main drug delivery technologies and key products within each of the categories
  • Asesses key products and technologies in clinical development
  • Provides a guide to optimizing drug reformulation processes
  • Provides a guide to business models of drug delivery companies
  • Identifies key issues facing drug delivery and pharmaceutical companies in the development of new drug delivery systems

Table of Contents

1 INTRODUCING THE FIELD OF DRUG DELIVERY 15

  • 1.1 THE VALUE OF DRUG DELIVERY SYSTEMS 15
  • 1.2 DRUG DELIVERY AND PRODUCT DIFFERENTIATION 16
  • 1.3 DRUG DELIVERY AND PATENT EXTENSION 17
  • 1.4 THE OPTIMAL TIME FOR REFORMULATION 19
  • 1.5 OPTIMIZING R&D RETURNS THROUGH DRUG DELIVERY 20
  • 1.6 OPPORTUNITIES AND THREATS TO THE DRUG DELIVERY SECTOR 20
  • 1.6.1 Opportunities for Growth in the Drug Delivery Sector 21
  • 1.6.2 Threats to Additional Growth in the Drug Delivery Sector 24
  • 1.7 BUSINESS MODELS OF DRUG DELIVERY COMPANIES 26

2 AN OVERVIEW OF DRUG DELIVERY TECHNOLOGIES 28

  • 2.1 ORAL DRUG DELIVERY 28
  • 2.1.1 Controlled Release 29
  • 2.1.2 Sustained Release 31
  • 2.1.3 Chronomodulation 31
  • 2.1.4 Rapid Dissolving and Taste-masking Tablets 31
  • 2.1.5 Macromolecular Drug Delivery 33
  • 2.1.6 Microemulsion 33
  • 2.1.7 Pulsatile Drug Delivery 34
  • 2.2 INHALABLE DRUG DELIVERY 35
  • 2.2.1 Nebulizers 36
  • 2.2.2 Metered Dose Inhalers (MDIs) 36
  • 2.2.3 Dry Powder Inhalers (DPIs) 37
  • 2.2.4 Limitations of Pulmonary Delivery Systems for Systemic Delivery 38
  • 2.2.5 Aqueous Systems 39
  • 2.2.6 Crystallization Technology 39
  • 2.2.7 Electrohydrodynamic (EHD) Aerosol Delivery 40
  • 2.2.8 Liposomal Systems 40
  • 2.3 INJECTABLE DRUG DELIVERY 41
  • 2.3.1 Sustained Release Injectable Systems 42
  • 2.3.2 Liposomal Systems 43
  • 2.3.3 Needleless Systems 43
  • 2.3.4 New Injectable Technologies 44
  • 2.4 TRANSMUCOSAL DRUG DELIVERY 44
  • 2.4.1 Buccal Delivery 45
  • 2.4.2 Nasal 47
  • 2.4.3 Rectal 48
  • 2.4.4 Vaginal 48
  • 2.5 TRANSDERMAL DRUG DELIVERY 49
  • 2.5.1 Passive Formulations 51
  • 2.5.2 Active Formulations 52
  • 2.6 NICHE TECHNOLOGIES 55
  • 2.6.1 Topical Systems 56
  • 2.6.2 Gene Delivery 58
  • 2.6.3 Implantable Systems 60
  • 2.6.4 Drug Delivery Microchips 63
  • 2.6.5 Nanotechnology 66

3 OVERVIEW OF GLOBAL DRUG DELIVERY MARKET 70

  • 3.1 IMPORTANCE OF DRUG DELIVERY 70
  • 3.2 GLOBAL DRUG DELIVERY MARKET BY GEOGRAPHIC AREA 71
  • 3.3 GLOBAL DRUG DELIVERY MARKET BY SEGMENT 72
  • 3.4 GLOBAL DRUG DELIVERY MARKET FORECASTS 74

4 DRUG DELIVERY MARKET ANALYSIS 77

  • 4.1 KEY MARKET SEGMENTS 77
  • 4.1.1 Oral Drug Delivery 77
  • 4.1.1.1 Sales of Products Utilizing Oral Drug Delivery Technology 77
  • 4.1.1.2 Key Therapeutic Areas for Oral Drug Delivery 84
  • 4.1.1.3 Key Oral Drug Delivery Products Impacting Global Market 86
  • 4.1.1.4 The Outlook for Oral Drug Delivery Technology 92
  • 4.1.1.5 Drivers and Restraints 93
  • 4.1.2 Inhalable Drug Delivery 93
  • 4.1.2.1 Sales of Products Utilizing Inhalable Drug Delivery Technology 93
  • 4.1.2.2 Key Therapeutic Areas for Inhalable Drug Delivery 96
  • 4.1.2.3 Key Inhalable Drug Delivery Products Impacting Global Market 97
  • 4.1.2.4 The Outlook for Inhalable Drug Delivery Technology 104
  • 4.1.2.5 Drivers and Restraints 105
  • 4.1.3 Injectable Drug Delivery 106
  • 4.1.3.1 Sales of Products Utilizing Injectable Drug Delivery Technology 106
  • 4.1.3.2 Key Therapeutic Areas for Injectable Drug Delivery 110
  • 4.1.3.3 Key Injectable Drug Delivery Products Impacting Global Market 113
  • 4.1.3.4 The Outlook for Injectable Drug Delivery Technology 116
  • 4.1.3.5 Drivers and Restraints 117
  • 4.1.4 Transmucosal Drug Delivery 117
  • 4.1.4.1 Sales of Products Utilizing Transmucosal Drug Delivery Technology 117
  • 4.1.4.2 Key Therapeutic Areas for Transmucosal Delivery 120
  • 4.1.4.3 Key Transmucosal Drug Delivery Products Impacting Global Market 121
  • 4.1.4.4 The Outlook for Transmucosal Drug Delivery Technology 125
  • 4.1.4.5 Drivers and Restraints 126
  • 4.1.5 Transdermal Drug Delivery 127
  • 4.1.5.1 Sales of Products Utilizing Transdermal Drug Delivery Technology 127
  • 4.1.5.2 Key Therapeutic Areas for Transdermal Drug Delivery 131
  • 4.1.5.3 Key Transdermal Drug Delivery Products Impacting Global Market 133
  • 4.1.5.4 The Outlook for Transdermal Drug Delivery Technology 137
  • 4.1.5.5 Drivers and Restraints 137
  • 4.1.6 Niche Drug Delivery Technologies 138
  • 4.1.6.1 Sales of Products Utilizing Niche Drug Delivery Technologies 138
  • 4.1.6.2 Key Niche Drug Delivery Technology Product Impacting Global Market 141
  • 4.1.6.3 The Outlook for Niche Drug Delivery Technologies 142
  • 4.1.6.4 Drivers and Restraints 143

5 EMERGING DRUG DELIVERY TECHNOLOGIES: ORAL DRUG DELIVERY 144

  • 5.1 KEY PRODUCT PROFILES 151
  • 5.2 KEY COMPANY INVOLVEMENT IN THE FIELD OF ORAL DRUG DELIVERY 156
  • 5.2.1 ALZA 156
  • 5.2.2 Biovail 157
  • 5.2.3 Cardinal Health 161
  • 5.2.4 Depomed 163
  • 5.2.5 Emisphere 163
  • 5.2.6 Ethypharm 164
  • 5.2.7 Penwest 166

6 EMERGING DRUG DELIVERY TECHNOLOGIES: INHALABLE DRUG DELIVERY 167

  • 6.1 KEY PRODUCT PROFILES 168
  • 6.2 KEY COMPANY INVOLVEMENT IN THE FIELD OF INHALABLE DRUG DELIVERY 171
  • 6.2.1 3M 171
  • 6.2.2 Alkermes 172
  • 6.2.3 Aradigm 172
  • 6.2.4 Nektar 173
  • 6.2.5 SkyePharma 175

7 EMERGING DRUG DELIVERY TECHNOLOGIES: INJECTABLE DRUG DELIVERY 176

  • 7.1 KEY PRODUCT PROFILES 179
  • 7.2 KEY COMPANY INVOLVEMENT IN THE FIELD OF INJECTABLE DRUG DELIVERY 182
  • 7.2.1 Alkermes 182
  • 7.2.2 ALZA 182
  • 7.2.3 Enzon 183
  • 7.2.4 Ethypharm 184
  • 7.2.5 Macromed 185
  • 7.2.6 Nektar 185
  • 7.2.7 QLT 186

8 EMERGING DRUG DELIVERY TECHNOLOGIES: TRANSMUCOSAL DRUG DELIVERY 188

  • 8.1 KEY PRODUCT PROFILES 190
  • 8.2 KEY COMPANY INVOLVEMENT IN THE FIELD OF TRANSMUCOSAL DRUG DELIVERY 193
  • 8.2.1 Generex 193
  • 8.2.2 Nastech 193
  • 8.2.3 Pherin 194

9 EMERGING DRUG DELIVERY TECHNOLOGIES: TRANSDERMAL DRUG DELIVERY 197

  • 9.1 KEY PRODUCT PROFILES 199
  • 9.2 KEY COMPANY INVOLVEMENT IN THE FIELD OF TRANSDERMAL DRUG DELIVERY 202
  • 9.2.1 3M 202
  • 9.2.2 Altea Therapeutics 203
  • 9.2.3 ALZA 204
  • 9.2.4 Aradigm 206
  • 9.2.5 Noven 207

10 EMERGING DRUG DELIVERY TECHNOLOGIES: NICHE DRUG DELIVERY TECHNOLOGIES 209

  • 10.1 KEY PRODUCT PROFILES 212
  • 10.2 KEY COMPANY INVOLVEMENT IN NICHE DRUG DELIVERY TECHNOLOGIES 216
  • 10.2.1 ALZA 216
  • 10.2.2 Connetics (now Stiefel Laboratories) 216
  • 10.2.3 Inovio 217
  • 10.2.4 MacroChem 218
  • 10.2.5 NexMed 218
  • 10.2.6 pSivida 219
  • 10.2.7 QLT 220
  • 10.2.8 SkyePharma 221

11 KEY DRUG DELIVERY COMPANY PROFILES 224

  • 11.1 3M PHARMACEUTICALS 224
  • 11.2 ALKERMES 226
  • 11.3 ALTEA THERAPEUTICS 227
  • 11.4 ALZA (JOHNSON & JOHNSON) 229
  • 11.5 ARADIGM 231
  • 11.6 BIOJECT 232
  • 11.7 BIOVAIL 234
  • 11.8 CARDINAL HEALTH 236
  • 11.9 CIMA LABS (CEPHALON) 237
  • 11.10 CONNETICS (STIEFEL LABORATORIES INC.) 239
  • 11.11 CYDEX PHARMACEUTICALS 241
  • 11.12 DELSITE BIOTECHNOLOGIES (CARRINGTON LABORATORIES) 242
  • 11.13 DEPOMED 243
  • 11.14 DOR BIOPHARMA 245
  • 11.15 DURECT 247
  • 11.16 EMISPHERE 249
  • 11.17 ENZON 251
  • 11.18 ETHYPHARM 253
  • 11.19 EURAND 255
  • 11.20 GENEREX 256
  • 11.21 INOVIO (FORMERLY GENETRONICS) 258
  • 11.22 IVAX (PART OF TEVA) 261
  • 11.23 MACROCHEM 262
  • 11.24 MACROMED (NOW PROTHERICS) 263
  • 11.25 NASTECH (NOW MDRNA) 265
  • 11.26 NEKTAR 266
  • 11.27 NEXMED 269
  • 11.28 NOVEN 270
  • 11.29 PSIVIDA 272
  • 11.30 PENWEST 274
  • 11.31 PHERIN PHARMACEUTICALS 276
  • 11.32 QLT 277
  • 11.33 SKYEPHARMA 279
  • 11.34 WATSON PHARMACEUTICALS 281
  • 11.35 ZOGENIX 283

Tables

  • TABLE 2.1 DRUGS SUITABLE OR UNSUITABLE FOR CONTROLLED RELEASE 30
  • TABLE 2.2 ADVANTAGES AND DISADVANTAGES OF TRANSDERMAL DELIVERY 50
  • TABLE 3.1 GLOBAL SALES OF DRUG DELIVERY SYSTEMS BY KEY SEGMENTS, 2007 72
  • TABLE 3.2 FORECAST GLOBAL SALES OF DRUG DELIVERY SYSTEMS BY SEGMENT, US$ BILLION 75
  • TABLE 4.1 KEY ORAL DRUG DELIVERY PRODUCTS, 2004-2007** ($ MN) 78
  • TABLE 4.2 LEADING ORAL DRUG DELIVERY COMPANIES 2007, KEY PRODUCTS AND SALES 2007 ($MN) 83
  • TABLE 4.3 KEY INHALABLE DRUG DELIVERY PRODUCTS, 2004-2007** ($ MN) 94
  • TABLE 4.4 KEY INJECTABLE DRUG DELIVERY PRODUCTS, 2004-2007** ($ MN) 106
  • TABLE 4.5 LEADING INJECTABLE DRUG DELIVERY COMPANIES 2007, KEY PRODUCTS AND SALES 2007 ($ MN) 109
  • TABLE 4.6 KEY TRANSMUCOSAL DRUG DELIVERY PRODUCTS, 2004-2007** 118 ($ MN) 118
  • TABLE 4.7 KEY TRANSDERMAL DRUG DELIVERY PRODUCTS, 2004-2007# 128 ($ MN) 128
  • TABLE 4.8 KEY TOPICAL DRUG DELIVERY PRODUCTS, 2007 138
  • TABLE 4.9 KEY NICHE DRUG DELIVERY PRODUCTS, 2004-2007 ($ MN) 140
  • TABLE 5.1 KEY ORAL DRUG DELIVERY R&D PIPELINE DRUGS, 2008 144
  • TABLE 6.1 KEY INHALABLE DRUG DELIVERY R&D PIPELINE DRUGS, 2008 167
  • TABLE 7.1 KEY INJECTABLE DRUG DELIVERY R&D PIPELINE DRUGS, 2008 176
  • TABLE 8.1 KEY TRANSMUCOSAL DRUG DELIVERY R&D PIPELINE DRUGS, 2008 188
  • TABLE 9.1 KEY TRANSDERMAL DRUG DELIVERY R&D PIPELINE DRUGS, 2008 197
  • TABLE 10.1 KEY TOPICAL DRUG DELIVERY R&D PIPELINE DRUGS, 2008 209
  • TABLE 10.2 KEY NICHE DRUG DELIVERY R&D PIPELINE DRUGS, 2008 210
  • TABLE 11.1 3M KEY FINANCIALS, 2003-2007 (US$MN) 224
  • TABLE 11.2 3M DRUG DELIVERY PORTFOLIO, 2008 225
  • TABLE 11.3 ALKERMES KEY FINANCIALS, 2003-2007 (US$MN) 226
  • TABLE 11.4 ALKERMES DRUG DELIVERY PORTFOLIO, 2008 227
  • TABLE 11.5 ALTEA THERAPEUTICS DRUG DELIVERY PORTFOLIO, 2008 228
  • TABLE 11.6 ALZA DRUG DELIVERY PORTFOLIO, 2008 229
  • TABLE 11.7 ARADIGM KEY FINANCIALS, 2003-2007 (US$MN) 231
  • TABLE 11.8 ARADIGM DRUG DELIVERY PORTFOLIO, 2008 232
  • TABLE 11.9 BIOJECT KEY FINANCIALS, 2003-2007 (US$MN) 233
  • TABLE 11.10 BIOJECT DRUG DELIVERY PORTFOLIO, 2008 233
  • TABLE 11.11 BIOVAIL KEY FINANCIALS, 2003-2007 (US$MN) 234
  • TABLE 11.12 BIOVAIL DRUG DELIVERY PORTFOLIO, 2008 235
  • TABLE 11.13 CARDINAL HEALTH KEY FINANCIALS, 2003-2007 (US$MN) 236
  • TABLE 11.14 CARDINAL HEALTH DRUG DELIVERY PORTFOLIO, 2008 237
  • TABLE 11.15 CEPHALON KEY FINANCIALS, 2003-2007 (US$MN) 238
  • TABLE 11.16 CIMA LABS DRUG DELIVERY PORTFOLIO, 2008 238
  • TABLE 11.17 CONNETICS KEY FINANCIALS, 2003-2007 (US$MN) 240
  • TABLE 11.18 CONNETICS DRUG DELIVERY PORTFOLIO, 2008 240
  • TABLE 11.19 CYDEX DRUG DELIVERY PIPELINE, 2008 242
  • TABLE 11.20 CARRINGTON LABORATORIES KEY FINANCIALS, 2003-2007 (US$MN) 243
  • TABLE 11.21 DEPOMED KEY FINANCIALS, 2003-2007 (US$MN) 244
  • TABLE 11.22 DEPOMED DRUG DELIVERY PORTFOLIO, 2008 245
  • TABLE 11.23 DOR BIOPHARMA KEY FINANCIALS, 2003-2007 (US$MN) 246
  • TABLE 11.24 DOR BIOPHARMA DRUG DELIVERY PORTFOLIO, 2008 246
  • TABLE 11.25 DURECT KEY FINANCIALS, 2003-2007 (US$MN) 247
  • TABLE 11.26 DURECT DRUG DELIVERY PORTFOLIO, 2008 248
  • TABLE 11.27 EMISPHERE KEY FINANCIALS, 2003-2007 (US$MN) 249
  • TABLE 11.28 EMISPHERE DRUG DELIVERY PORTFOLIO, 2008 250
  • TABLE 11.29 ENZON KEY FINANCIALS, 2003-2007 (US$MN) 251
  • TABLE 11.30 ENZON DRUG DELIVERY PORTFOLIO, 2008 252
  • TABLE 11.31 ETHYPHARM DRUG DELIVERY PORTFOLIO, 2008 253
  • TABLE 11.32 EURAND KEY FINANCIALS, 2003-2007 (US$MN) 255
  • TABLE 11.33 EURAND DRUG DELIVERY PORTFOLIO, 2008 256
  • TABLE 11.34 GENEREX KEY FINANCIALS, 2003-2007 (US$MN) 257
  • TABLE 11.35 GENEREX DRUG DELIVERY PORTFOLIO, 2008 257
  • TABLE 11.36 INOVIO KEY FINANCIALS, 2003-2007 (US$MN) 258
  • TABLE 11.37 INOVIO DRUG DELIVERY PORTFOLIO, 2008 259
  • TABLE 11.38 IVAX KEY FINANCIALS, 2003-2007 (US$MN) 261
  • TABLE 11.39 IVAX DRUG DELIVERY PORTFOLIO, 2008 262
  • TABLE 11.40 MACROCHEM KEY FINANCIALS, 2003-2007 (US$MN) 263
  • TABLE 11.41 MACROCHEM DRUG DELIVERY PORTFOLIO, 2008 263
  • TABLE 11.42 MACROMED DRUG DELIVERY PORTFOLIO, 2008 264
  • TABLE 11.43 NASTECH KEY FINANCIALS, 2003-2007 (US$MN) 265
  • TABLE 11.44 NASTECH DRUG DELIVERY PORTFOLIO, 2008 266
  • TABLE 11.45 NEKTAR KEY FINANCIALS, 2003-2007 (US$MN) 267
  • TABLE 11.46 NEKTAR DRUG DELIVERY PORTFOLIO, 2008 267
  • TABLE 11.47 NEXMED KEY FINANCIALS, 2003-2007 (US$MN) 269
  • TABLE 11.48 NEXMED DRUG DELIVERY PORTFOLIO, 2008 270
  • TABLE 11.49 NOVEN KEY FINANCIALS, 2003-2007 (US$MN) 271
  • TABLE 11.50 NOVEN DRUG DELIVERY PORTFOLIO, 2008 271
  • TABLE 11.51 PSIVIDA KEY FINANCIALS, 2003-2007 (US$MN) 273
  • TABLE 11.52 PSIVIDA DRUG DELIVERY PORTFOLIO, 2008 273
  • TABLE 11.53 PENWEST KEY FINANCIALS, 2003-2007 (US$MN) 274
  • TABLE 11.54 PENWEST DRUG DELIVERY PORTFOLIO, 2008 275
  • TABLE 11.55 PHERIN PHARMACEUTICALS DRUG DELIVERY PORTFOLIO, 2008 276
  • TABLE 11.56 QLT KEY FINANCIALS, 2003-2007 (US$MN) 277
  • TABLE 11.57 QLT DRUG DELIVERY PORTFOLIO, 2008 278
  • TABLE 11.58 SKYE PHARMA KEY FINANCIALS, 2003-2007 (US$MN) 279
  • TABLE 11.59 SKYEPHARMA DRUG DELIVERY PORTFOLIO, 2008 280
  • TABLE 11.60 WATSON KEY FINANCIALS, 2003-2007 (US$MN) 281
  • TABLE 11.61 WATSON PHARMACEUTICALS DRUG DELIVERY PORTFOLIO, 2008 282
  • TABLE 11.62 ZOGENIX PHARMACEUTICALS DRUG DELIVERY PORTFOLIO, 2008 283

Graphs

  • GRAPH 3.1 ESTIMATED DRUG DELIVERY MARKET BY MAIN GEOGRAPHIC REGIONS 71
  • GRAPH 3.2 GLOBAL SALES OF DRUG DELIVERY SYSTEMS BY KEY SEGMENTS, 2007 73
  • GRAPH 3.3 FORECAST GLOBAL SALES OF DRUG DELIVERY MARKET BY SEGMENT, US$ BILLION 75
  • GRAPH 3.4 FORECAST 2007-2012 GROWTH OF GLOBAL DRUG DELIVERY MARKET BY SEGMENT 76
  • GRAPH 4.1 TOP 5 PRODUCTS UTILIZING ORAL DELIVERY, GLOBAL SALES 2007 ($ MN) 82
  • GRAPH 4.2 LEADING ORAL DRUG DELIVERY COMPANIES, COMBINED KEY PRODUCT VALUES 2007 ($ MN) 84
  • GRAPH 4.3 KEY THERAPEUTIC AREAS OF EMPHASIS FOR ORAL DRUG DELIVERY, # OF KEY MARKETED PRODUCTS, 2007 85
  • GRAPH 4.4 TOP 5 PRODUCTS UTILIZING INHALABLE DELIVERY, GLOBAL SALES 2007 ($ MN) 96
  • GRAPH 4.5 INHALABLE DRUG DELIVERY MARKET SHARE, BY TECHNOLOGY 2007 96
  • GRAPH 4.6 TOP 5 PRODUCTS UTILIZING INJECTABLE DELIVERY, GLOBAL SALES 2007 ($ MN) 108
  • GRAPH 4.7 LEADING INJECTABLE DRUG DELIVERY COMPANIES, COMBINED KEY PRODUCT VALUES 2007 ($ MN) 110
  • GRAPH 4.8 TOP 5 PRODUCTS UTILIZING TRANSMUCOSAL DELIVERY, GLOBAL SALES 2007 ($ MN) 119
  • GRAPH 4.9 LEADING DEVELOPERS OF TRANSMUCOSAL-BASED THERAPEUTICS 2007 ($ MN) 120
  • GRAPH 4.10 LEADING TRANSDERMAL DRUG DELIVERY COMPANIES, BY # OF PRODUCTS ON MARKET 130
  • GRAPH 4.11 KEY THERAPEUTIC AREAS OF EMPHASIS FOR TRANSDERMAL DRUG DELIVERY, # OF KEY MARKETED PRODUCTS 131
  • GRAPH 5.1 LEADING COMPANIES ACTIVE IN ORAL DRUG DELIVERY DEVELOPMENT 150
  • GRAPH 5.2 LEADING INDICATIONS FOR ORAL DRUG DELIVERY PRODUCTS IN DEVELOPMENT 151
  • GRAPH 6.1 LEADING COMPANIES ACTIVE IN INHALABLE DRUG DELIVERY DEVELOPMENT 168
  • GRAPH 7.1 LEADING COMPANIES ACTIVE IN INJECTABLE DRUG DELIVERY DEVELOPMENT 179
  • GRAPH 8.1 LEADING COMPANIES ACTIVE IN INJECTABLE DRUG DELIVERY DEVELOPMENT 189
  • GRAPH 9.1 LEADING COMPANIES ACTIVE IN TRANSDERMAL DRUG DELIVERY DEVELOPMENT 198
  • GRAPH 10.1 LEADING COMPANIES ACTIVE IN NICHE/TOPICAL DRUG DELIVERY DEVELOPMENT 211

Figures

  • FIGURE 1.1 OPTIMAL TIME FOR REFORMULATION 19
  • FIGURE 1.2 GROWTH PROSPECTS IN THE DRUG DELIVERY SECTOR 21
  • FIGURE 2.1 PULSATILE DRUG RELEASE 34
Back to Top